From The Labs Archives - Page 10 of 96 - Baylor College of Medicine Blog Network

A man rubbing his eyes and holding his glasses

Chronic jet lag leads to human liver cancer in a mouse model

February 6, 2024 carcinogen, circadian rhythm, circadian rhythm disruption, jetlag, liver cancer, Research

This study shows that circadian influences in cancer cannot be underestimated – chronic circadian dysfunction is a human carcinogen

From The Labs

Video of the Month: The developing embryo

February 1, 2024 brain development, embryo development, Foxi3, imaging, Research

This 3D rotating visualization of a developing embryo shows the locations of proteins involved in orchestrating this complex process.

From The Labs

And the awards go to…

January 30, 2024 Awards, cancer neuroscience, Gruber Prize, Human genetics, Marcus Foundation, MasSpecPen, Research, TAMEST

The new year started with a bang! at Baylor College of Medicine. Three faculty members have received major recognitions for their achievements in basic science research and technology development.

From The Labs

Improving the detection of potential therapeutic tumor targets in human biopsies

January 25, 2024 biopsy, Breast Cancer, KiP, Mass Spectrometry Proteomics, protein kinases, Research, tumor targets

The method holds great promise for better definition of the individual druggable landscape present in each cancer.

From The Labs

Finding a food-cancer connection: How what you eat might affect your cancer risk

January 23, 2024 Colon Cancer, diet and cancer risk, early onset colon cancer, epigenetics, folate, folate food fortification, gene p16, Research

This study reveals a mechanism by which the environment, diet in this case, can influence cancer risk.

From The Labs

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

January 19, 2024 cancer therapy, CAR Tcells, CD5, clinical trial, Research, T cell lymphoma

A first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of anti-tumor efficacy and safety.